Gain Therapeutics, Inc. (GANX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 58/100 (HIGH), 11.1 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.93% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
- Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
- Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
- Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
- Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
- Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
- Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
- Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Sudden Gains in Cognitive-Behavioral Therapy for Seasonal Affective Disorder. — Cognit Ther Res 2025 Dec PMID 42825220
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Gain Therapeutics, Inc..
Full GANX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.